A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. - Mayer, E L; DeMichele, A; Rugo, H S; Miller, K; Waks, A G; Come, S E; Mulvey, T; Jeselsohn, R; Overmoyer, B; Guo, H; Barry, W T; Bartlett, C Huang; et al. (Annals of Oncology, 2019)